Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

Last Close
Nov 14 01:34PM ET
3.40
Dollar change
-0.34
Percentage change
-9.08
%
Index- P/E- EPS (ttm)-2.67 Insider Own- Shs Outstand136.43M Perf Week-15.83%
Market Cap523.27M Forward P/E- EPS next Y-1.10 Insider Trans- Shs Float82.85M Perf Month-33.06%
Income-220.93M PEG- EPS next Q- Inst Own4.60% Short Float0.09% Perf Quarter32.31%
Sales0.13M P/S4025.17 EPS this Y36.66% Inst Trans- Short Ratio2.86 Perf Half Y-10.52%
Book/sh-0.56 P/B- EPS next Y36.88% ROA-153.73% Short Interest0.07M Perf Year88.91%
Cash/sh1.12 P/C3.03 EPS next 5Y9.40% ROE-3388.40% 52W Range1.72 - 5.45 Perf YTD15.26%
Dividend Est.- P/FCF- EPS past 5Y-44.08% ROI-177.13% 52W High-37.61% Beta-
Dividend TTM- Quick Ratio2.94 Sales past 5Y16.91% Gross Margin17.35% 52W Low97.69% ATR (14)0.26
Dividend Ex-Date- Current Ratio2.94 EPS Y/Y TTM-26.35% Oper. Margin-153997.10% RSI (14)29.55 Volatility5.84% 5.46%
Employees- Debt/Eq- Sales Y/Y TTM15.94% Profit Margin-176590.81% Recom1.29 Target Price10.90
Option/ShortNo / Yes LT Debt/Eq- EPS Q/Q-51.41% Payout- Rel Volume8.12 Prev Close3.74
Sales Surprise382.80% EPS Surprise-267.89% Sales Q/Q14.26% EarningsAug 30 AMC Avg Volume25.72K Price3.40
SMA20-20.61% SMA50-18.31% SMA2004.96% Trades Volume136,102 Change-9.08%
Date Action Analyst Rating Change Price Target Change
Dec-08-22Initiated H.C. Wainwright Buy $14
Apr-26-22Initiated SVB Leerink Outperform $25
Nov-17-20Initiated Citigroup Buy $48
Nov-11-20Initiated Truist Buy $25
Nov-11-20Initiated SVB Leerink Outperform $33
Nov-11-20Initiated Oppenheimer Outperform $36
Nov-12-24 07:00AM
Nov-04-24 07:00AM
Oct-16-24 07:00AM
Oct-10-24 07:30AM
Oct-08-24 07:00AM
07:30AM Loading…
Sep-30-24 07:30AM
Sep-23-24 07:00AM
Sep-18-24 07:30AM
Sep-10-24 07:30AM
Sep-05-24 06:00AM
Sep-03-24 07:30AM
Aug-31-24 05:14PM
Aug-30-24 07:30AM
Aug-08-24 08:10AM
Jul-17-24 07:15AM
09:46PM Loading…
Jul-14-24 09:46PM
Jul-09-24 07:30AM
Jun-18-24 08:57PM
Jun-13-24 07:58PM
Jun-11-24 09:13PM
Jun-03-24 07:30AM
May-28-24 07:30AM
May-01-24 07:30AM
Apr-25-24 09:00AM
Apr-08-24 06:42PM
Apr-04-24 06:34PM
Apr-03-24 05:39PM
Mar-24-24 07:55AM
Mar-19-24 06:00AM
Mar-05-24 05:08PM
05:55PM Loading…
Feb-28-24 05:55PM
Feb-19-24 06:25PM
Feb-14-24 07:00AM
Feb-05-24 03:11AM
Feb-01-24 06:00AM
Dec-27-23 06:00AM
Dec-19-23 06:00AM
Dec-01-23 05:30AM
Nov-09-23 05:30AM
Oct-30-23 05:30AM
Oct-27-23 05:30AM
Oct-02-23 05:30AM
Sep-07-23 05:30AM
Aug-28-23 05:30AM
Jul-26-23 06:00AM
Jul-24-23 06:00AM
Jul-13-23 06:00AM
Jul-10-23 06:00AM
Jun-08-23 06:00AM
May-25-23 08:00AM
06:00AM
May-17-23 06:00AM
May-08-23 05:30AM
Apr-28-23 05:30AM
Mar-07-23 06:00AM
Mar-06-23 06:00AM
Feb-13-23 06:00AM
Feb-06-23 06:00AM
Jan-30-23 06:00AM
Dec-12-22 10:08AM
Dec-09-22 03:00PM
Dec-06-22 06:00AM
Nov-10-22 06:00AM
Oct-24-22 06:00AM
Sep-18-22 07:15PM
Aug-30-22 06:00AM
Aug-16-22 07:46AM
Aug-14-22 09:02PM
09:01PM
Jun-19-22 07:05PM
May-11-22 08:00AM
May-10-22 08:20AM
May-05-22 06:00AM
Apr-29-22 06:00AM
Apr-22-22 08:15AM
Apr-10-22 08:12PM
Mar-21-22 04:00AM
Mar-10-22 06:00AM
Mar-02-22 06:00AM
Feb-14-22 09:06AM
06:00AM
Feb-10-22 06:00AM
Feb-09-22 06:00AM
Jan-24-22 06:00AM
Jan-10-22 05:59PM
Jan-04-22 06:18AM
Jan-03-22 06:00AM
Oct-26-21 06:00AM
Oct-19-21 06:00AM
Oct-12-21 05:41PM
Oct-04-21 07:00AM
Sep-07-21 08:20PM
Sep-02-21 07:00AM
Aug-30-21 07:00AM
Aug-10-21 07:00AM
Aug-09-21 07:00AM
Jul-06-21 07:00AM
Jun-16-21 04:06PM
Jun-15-21 12:27PM
Jun-14-21 07:00AM
Opthea Ltd. is a clinical stage biopharmaceutical company, which engages in the development of biological therapeutics for the treatment of progressive retinal diseases. It focuses on treating neovascular age-related macular degeneration and diabetic macular edema, which causes visual impairment among elderly and diabetic patients. The company was founded on October 17, 1984, and is headquartered in South Yarra, Australia.